SLC5A2 and chronic kidney disease: Having been up until the recent discoveries regarding SGLT2 inhibitors the only medications known to attenuate progression of CKD, the RAAS blockers were a noted part of many, if not most, of the discussed trials about SGLT2i, as shown in Table 1.